Vascular Endothelial Growth Factor Receptor-2 in Macular Oedema with Retinal Vein Occlusion

PurposeReport 5-year outcomes of patients receiving anti-vascular endothelial growth factor (VEGF) for the treatment of macular oedema secondary to retinal vein occlusion (RVO.MethodsRetrospective review of eyes with RVO which initiated anti-VEGF treatment. Data including age, gender, visual acuity (VA) and injection numbers were obtained from medical records. Optical coherence tomography scans were graded for presence or absence of macular oedema and central foveal thickness (CFT). Macular perfusion was assessed on fundus fluorescein angiography by masked graders.Results68 eyes (31 branch RVO, BRVO; 35 central RVO, CRVO and 2 hemi-RVO) with 5 years of follow-up after initiation of anti-VEGF treatment. Mean change in VA at 5 years was + 9.6 ± 21.6 letters among CRVO eyes and + 14.2 ± 15.6 letters among eyes with BRVO (p=0.001). Vision of 20/40 or better was achieved in 65 % of treated eyes. The proportion of eyes with a three-line improvement of vision (15 letters) at 5 years was 22 %. Mean CFT decreased by 257.6 ± 249.8 µm in eyes with CRVO and 145.6 ± 143.3 µm in eyes with BRVO.ConclusionThe results confirm good long-term outcomes can be achieved with anti-VEGF therapy for RVO.

Download Full-text

Aqueous Soluble Vascular Endothelial Growth Factor Receptor-2 in Macular Edema with Branch Retinal Vein Occlusion

Current Eye Research ◽

10.3109/02713683.2013.821135 ◽

2013 ◽

Vol 38 (12) ◽

pp. 1288-1290 ◽

Cited By ~ 6

Author(s):

Hidetaka Noma ◽

Tatsuya Mimura

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Vein Occlusion ◽

Endothelial Growth Factor

Download Full-text

Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion

British Journal of Ophthalmology ◽

10.1136/bjo.2010.192468 ◽

2010 ◽

Vol 95 (6) ◽

pp. 788-792 ◽

Cited By ~ 26

Author(s):

H. Noma ◽

H. Funatsu ◽

T. Mimura ◽

S. Eguchi ◽

K. Shimada

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Central Retinal Vein Occlusion ◽

Macular Oedema ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Vein Occlusion ◽

Endothelial Growth Factor ◽

Central Retinal Vein

Download Full-text

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd007325.pub3 ◽

2014 ◽

Cited By ~ 25

Author(s):

Tasanee Braithwaite ◽

Afshan A Nanji ◽

Kristina Lindsley ◽

Paul B Greenberg

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Macular Oedema ◽

Vascular Endothelial ◽

Vein Occlusion ◽

Endothelial Growth Factor ◽

Central Retinal Vein

Download Full-text

Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema

European Journal of Ophthalmology ◽

10.1177/1120672119885054 ◽

2019 ◽

pp. 112067211988505 ◽

Cited By ~ 2

Author(s):

Hidetaka Noma ◽

Kanako Yasuda ◽

Masahiko Shimura

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Branch Retinal Vein Occlusion ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Intravitreal Ranibizumab ◽

Vein Occlusion ◽

Endothelial Growth Factor

Purpose: To investigate the relations of vascular endothelial growth factor, growth factors, soluble vascular endothelial growth factor receptors, and inflammatory factors to recurrence of macular edema after anti-vascular endothelial growth factor therapy in patients with branch retinal vein occlusion. Methods: This study retrospectively investigated 17 patients with branch retinal vein occlusion who received intravitreal ranibizumab injection three times within 6 months for recurrent macular edema. Aqueous humor samples were obtained from these patients at every recurrence. Levels of soluble vascular endothelial growth factor receptor-1, soluble vascular endothelial growth factor receptor-2, vascular endothelial growth factor, placental growth factor, platelet-derived growth factor-AA, soluble intercellular adhesion molecule-1, monocyte chemoattractant protein-1, interleukin-6, interleukin-8, interleukin-12(p70), and interleukin-13 were measured by the suspension array method. Aqueous flare values were measured with a laser flare meter and central macular thickness was determined by optical coherence tomography. Results: Mean best-corrected visual acuity and central macular thickness improved significantly over time after intravitreal ranibizumab injection, but the aqueous flare value at recurrence after intravitreal ranibizumab injection showed no significant change compared with baseline. Aqueous humor levels of soluble vascular endothelial growth factor receptor-1, soluble vascular endothelial growth factor receptor-2, vascular endothelial growth factor, platelet-derived growth factor-AA, monocyte chemoattractant protein-1, and interleukin-8 decreased significantly over time after intravitreal ranibizumab injection. However, there were no significant changes of the other five factors/cytokines (placental growth factor, soluble intercellular adhesion molecule-1, interleukin-6, interleukin-12, and interleukin-13) at recurrence after intravitreal ranibizumab injection compared with baseline. Conclusion: These findings suggest that persistent inflammation may influence the recurrence of macular edema in branch retinal vein occlusion patients, and that adding steroid therapy might be an effective strategy for preventing recurrence.

Download Full-text